European Growth Companies With High Insider Ownership And Up To 18% Revenue Growth
In recent weeks, European markets have navigated a complex landscape marked by robust corporate earnings and geopolitical tensions that have driven oil prices higher. Amid this backdrop, growth companies with high insider ownership can offer unique insights into potential resilience and alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| MilDef Group (OM:MILDEF) | 10.3% | 30.9% |
| Kuros Biosciences (SWX:KURN) | 26.1% | 58.4% |
| KebNi (OM:KEBNI B) | 11.8% | 90.9% |
| Hacksaw (OM:HACK) | 13.2% | 23.7% |
| Dellia Group (OB:DELIA) | 29.9% | 47.9% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.7% | 73.9% |
| CD Projekt (WSE:CDR) | 35.2% | 30.7% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.8% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 50.2% |
Let's explore several standout options from the results in the screener.
STIF Société anonyme (ENXTPA:ALSTI)
Simply Wall St Growth Rating: ★★★★★☆
Overview: STIF Société anonyme manufactures and sells components for the handling of bulk products in France, with a market cap of €264.48 million.
Operations: The company's revenue is generated from Handling Equipment (€19.60 million), Explosion Energy (BESS) (€41.40 million), US Distribution Segment (€4.40 million), Active Industry Explosion (€6.80 million), and Passive Industry Explosion (€16.60 million).
Insider Ownership: 11.6%
Revenue Growth Forecast: 16.2% p.a.
STIF Société anonyme is positioned as a growth company in Europe, with earnings forecast to grow 21.3% annually, outpacing the French market. Despite its high debt level, its return on equity is projected to reach 32.1% in three years. The company's revenue is expected to increase by 16.2% per year, surpassing the market average of 5.7%. It trades at a significant discount of 47.6% below estimated fair value, enhancing its investment appeal despite limited insider trading data recently available.
- Unlock comprehensive insights into our analysis of STIF Société anonyme stock in this growth report.
- The valuation report we've compiled suggests that STIF Société anonyme's current price could be inflated.
Hanza (OM:HANZA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Hanza AB (publ) is a company that offers contract manufacturing solutions across various regions including Sweden, Finland, and North America, with a market cap of SEK8.63 billion.
Operations: The company's revenue segments include Main Markets generating SEK5.32 billion and Other Markets contributing SEK3.13 billion, with Business Development and Services adding SEK11 million.
Insider Ownership: 24.5%
Revenue Growth Forecast: 18.5% p.a.
HANZA is experiencing robust growth, with earnings projected to increase by 33.6% annually, significantly outpacing the Swedish market. The recent strategic reorganization and share repurchase program aim to enhance capital structure and operational efficiency. Despite a volatile share price, insider buying has been substantial in the past three months. Trading at 61.6% below estimated fair value, HANZA's current initiatives could position it favorably for future expansion amidst high insider ownership trends in Europe.
- Navigate through the intricacies of Hanza with our comprehensive analyst estimates report here.
- Upon reviewing our latest valuation report, Hanza's share price might be too pessimistic.
Redcare Pharmacy (XTRA:RDC)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Redcare Pharmacy NV operates an online pharmacy business across several European countries, including the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France with a market cap of €1.36 billion.
Operations: The company's revenue is derived from the DACH region, contributing €2.51 billion, and international markets, adding €561.20 million.
Insider Ownership: 12.1%
Revenue Growth Forecast: 10.7% p.a.
Redcare Pharmacy is trading at 80% below its estimated fair value, despite recent volatility and significant insider selling. The company's revenue is forecast to grow 10.7% annually, outpacing the German market's growth rate. Although Redcare reported a net loss for the first half of 2026, it raised its full-year earnings guidance to reflect higher expected revenue growth of 15% to 17%.
- Delve into the full analysis future growth report here for a deeper understanding of Redcare Pharmacy.
- Upon reviewing our latest valuation report, Redcare Pharmacy's share price might be too optimistic.
Make It Happen
- Discover the full array of 215 Fast Growing European Companies With High Insider Ownership right here.
- Ready To Venture Into Other Investment Styles? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com